Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balinatunfib on Cardiac Repolarization in Healthy Adult Participants
NCT07272629Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of balinatunfib (4 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in the QT interval corrected using the Fridericia formula. Started Dec 2025; status: completed.
02
Drugs
balinatunfib
Beyond the preview
Go deeper on NCT07272629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272629.